<DOC>
	<DOCNO>NCT00927615</DOCNO>
	<brief_summary>The primary objective study investigate whether intracoronary bolus administration abciximab superior intravenous bolus administration improve myocardial perfusion patient ST-segment elevation myocardial infarction undergo primary percutaneous coronary intervention .</brief_summary>
	<brief_title>Comparison Intracoronary Versus Intravenous Abciximab ST-segment Elevation Myocardial Infarction ( CICERO )</brief_title>
	<detailed_description>The contemporary management ST-segment elevation myocardial infarction ( STEMI ) consist primary percutaneous coronary intervention ( PCI ) include thrombus aspiration stenting . There , however , still high incidence impair post-procedural myocardial perfusion , associate poorer clinical outcome . Intravenous ( IV ) administration glycoprotein IIb/IIIa inhibitor abciximab primary PCI play important role treatment patient STEMI . With high local drug concentration , abciximab may additional anti-platelet , anti-thrombotic anti-inflammatory feature . These possible benefit may obtain intracoronary ( IC ) administration abciximab . Recent small- medium-scaled study suggest IC administration abciximab instead ( IV ) route associate improved post-procedural myocardial perfusion clinically relevant reduction major adverse cardiac event . Because limited number patient include study , large randomize clinical trial need evaluate effect IC abciximab patient STEMI . Furthermore , combine strategy PCI thrombus aspiration IC use abciximab investigate . Therefore , investigator intend evaluate effect IC bolus administration abciximab compare IV bolus administration post-procedural myocardial perfusion assess extent ST-segment elevation resolution patient STEMI undergo primary PCI . The study single-center , prospective , randomized trial blind evaluation endpoint .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>diagnosis STEMI define chest pain suggestive myocardial ischemia least 30 minute hospital admission time onset symptom less 12 hour ECG STsegment deviation 0.1 mV 2 lead rescue PCI thrombolytic therapy need emergency coronary artery bypass graft presence cardiogenic shock know existence lifethreatening disease life expectancy le 6 month inability provide inform consent contraindication use abciximab ( active internal bleeding , history stroke within 2 year , recent major surgery intracranial intraspinal trauma surgery within 2 month , intracranial neoplasm , arteriovenous malformation aneurysm , bleed diathesis , severe uncontrolled hypertension , thrombocytopenia , vasculitis , hypertensive diabetic retinopathy , severe liver kidney failure , hypersensitivity murine protein )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>myocardial infarction</keyword>
	<keyword>glycoprotein IIb/IIIa</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>thrombus aspiration</keyword>
	<keyword>myocardial perfusion</keyword>
</DOC>